Cel
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is used in immunodeficiencies & blood malignancies though costly, hard-to-access & linked to many severe complications. Smart Immune puts forth a high-profile solution to solve this gap: ProTcell platform supplies clinical-grade, allogeneic lymphoid progenitor cells produced in just 7 days ex-vivo. These are made into tolerant polyclonal mature T cells by the patient’s own thymus in a record <3 months (vs. 15-24 months naturally), & reducing complications since infused in our 1st patient (June 2020). With strong IP, orphan drug label secured & traction across eminent KOLs in >7 countries, we face a window opportunity. With the EIC’s support, we pursue the less attractive-to-VC’s SCID indication, as part of our Series A, to become a front row T-cell therapy player, with future chimeric antigen receptor (CAR) therapies in mind. We project to treat >40k patients by 2030 & recover a ROI of 5,28 over our target Series A.
Dziedzina nauki
Słowa kluczowe
Program(-y)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Zaproszenie do składania wniosków
HORIZON-EIC-2023-ACCELERATOR-01
Zobacz inne projekty w ramach tego zaproszeniaSystem finansowania
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceKoordynator
75006 Paris
Francja
Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.